Search results
Results from the WOW.Com Content Network
Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. [ 6 ] [ 7 ] [ 10 ] It is also used to treat adults with heart failure and chronic kidney disease .
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
This pharmacology -related article is a stub. You can help Wikipedia by expanding it.
AstraZeneca's (AZN) diabetes drug gets approval in Europe for type-1 diabetes as an adjunct to insulin in patients with a BMI greater or equal to 27 kg/m2.
Negotiations with participating drug companies will occur in 2025, and any negotiated prices will go into effect in 2027. Drug companies with a selected drug will have until the end of February to ...
Forxiga ™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes Forxiga, a once-daily oral agent, provides ...
[15] [16] Because the drug was the first GLP-1 agonist that could be taken once a day, sales projections in 2013 were €500M per year by 2018. [16] Sanofi resubmitted the application which the FDA accepted in September 2015, by which time Sanofi had lost the lead in the field of anti-diabetic drugs to Novo Nordisk. [17]
Insilico has a long way to go, and other hurdles to clear, before its AI-generated drug hits the market, but the potential to speed up the timeline for introducing new medications and other ...